Athenex, texas children's cancer center, and the center for cell and gene therapy at baylor college of medicine to present phase 1 clinical data for kur-501, an autologous gd2 car-nkt cell therapy for relapsed/refractory high risk neuroblastoma at the asgct 25th annual meeting

Buffalo, n.y., may 02, 2022 (globe newswire) -- athenex (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the company will present at the upcoming asgct 25th annual meeting, taking place may 16-19, 2022, in washington, d.c. the abstract associated with the presentation is now available on the conference website.
ATNX Ratings Summary
ATNX Quant Ranking